Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Identification of Causal Genetic Events in Oral Cancer Progression
FY 2009-10
Summary
Oral cancer is mainly caused by smoking, chewing tobacco, or alcohol consumption. Since these activities can be found around the world, oral tumors represent the most frequently occurring subtype of head and neck malignancies and one of the most common global causes of cancer death. Survival rates for oral cancers are particularly low because tumors are often diagnosed at late, advanced stages and have a high rate of recurrence.
For many cancer types, early detection is key to an improved clinical outcome. While the oral cavity is easily investigated for precancerous disease, there are currently no tools that allow clinicians to determine whether a given low grade oral lesion is likely to progress to an invasive tumor. "Watchful waiting" is the standard clinical approach in these cases since only a small fraction will progress; intervention for all lesions at this stage would be impractical and result in over-treatment for a majority of patients. Unfortunately, waiting means that the opportunity for early intervention in cases that will progress is lost. Tools that will allow us to determine the progression risk for each low grade precancerous lesion are urgently needed.
In order to address this clinical challenge, I have begun to investigate the molecular alterations that underlie the earliest stages of oral cancer. By doing this, I will uncover the specific gene changes that drive the initiation and progression of this disease. When we are able to associate these changes with specific clinical outcomes, we will have a biomarker we can use to identify early stage patients that require aggressive intervention. An additional benefit from this analysis is that cancer associated genes I uncover will also be useful as targets for the next generation of therapies being developed for oral cancer. Taken together, this project has excellent potential to impact on oral cancer patient care and improve outcomes for patients with this disease.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
201564
Name
Hughes Shevaun E
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Identification of Causal Genetic Events in Oral Cancer Progression
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Array Cgh; Biomarkers; Copy Number; Dysplasia; Genetics; Head And Neck; Oncogene/Tumor Suppressor Gene; Oral Cancer; Progression; Tumorigenesis
Abstract
Oral cancer is mainly caused by smoking, chewing tobacco, or alcohol consumption. Since these activities can be found around the world, oral tumors represent the most frequently occurring subtype of head and neck malignancies and one of the most common global causes of cancer death. Survival rates for oral cancers are particularly low because tumors are often diagnosed at late, advanced stages and have a high rate of recurrence.
For many cancer types, early detection is key to an improved clinical outcome. While the oral cavity is easily investigated for precancerous disease, there are currently no tools that allow clinicians to determine whether a given low grade oral lesion is likely to progress to an invasive tumor. "Watchful waiting" is the standard clinical approach in these cases since only a small fraction will progress; intervention for all lesions at this stage would be impractical and result in over-treatment for a majority of patients. Unfortunately, waiting means that the opportunity for early intervention in cases that will progress is lost. Tools that will allow us to determine the progression risk for each low grade precancerous lesion are urgently needed.
In order to address this clinical challenge, I have begun to investigate the molecular alterations that underlie the earliest stages of oral cancer. By doing this, I will uncover the specific gene changes that drive the initiation and progression of this disease. When we are able to associate these changes with specific clinical outcomes, we will have a biomarker we can use to identify early stage patients that require aggressive intervention. An additional benefit from this analysis is that cancer associated genes I uncover will also be useful as targets for the next generation of therapies being developed for oral cancer. Taken together, this project has excellent potential to impact on oral cancer patient care and improve outcomes for patients with this disease.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hughes, Shevaun E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~